4 results
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in patients of all ages with mild (FVIII level between > 5% and < 40%) or moderate hemophilia A (FVIII level between >= 1% and…
To evaluate whether doxepin hydrochloride 5% cream is more effective in reducing pruritus in burn patients than standard treatment (clemastine).
The primary objective is to determine whether subjects with CIDP are overtreated with maintenance IVIg treatment and to reduce overtreatment-associated subjects* burden and health care costs.
to evaluate whether Doxepin hydrochloride 5% cream versus a placebo cream significantly reduces pruritus in burn patients by comparing itch scores.